VIDEO: Results of real-world suprachoroidal triamcinolone acetonide positive

CHICAGO — In this Healio Video Perspective from the AAO meeting, Dilraj Grewal, MD, FASRS, of Duke Eye Center shares real-world data on suprachoroidal triamcinolone acetonide for noninfectious uveitis with macular edema.

In a retrospective analysis, 27 eyes were treated with a suprachoroidal injection of triamcinolone acetonide 40 mg and were followed for a minimum of 3 months. Overall, there were improvements in visual acuity, central subfield thickness and cystoid macular edema, with a positive safety profile.

According to Grewal, the analysis “gives us greater confidence on the real-world usage of suprachoroidal triamcinolone acetonide.”

Published by:

Sources/Disclosures

Collapse

Source:

Zheng Y, et al. Real-world outcomes of suprachoroidal injection of triamcinolone acetonide for noninfectious uveitis. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.

Disclosures:
Grewal reports no relevant financial disclosures.

Read more about

This post was originally published on this site